Hapten-directed targeting to single-chain antibody receptors

Tian Lu Cheng, Kuang-Wen Liao, Shey-Cherng Tzou, Chiu Min Cheng, Bing Mae Chen, Steve R. Roffler*


研究成果: Article同行評審

16 引文 斯高帕斯(Scopus)


Artificial recombinant receptors may be useful for selectively targeting imaging and therapeutic agents to sites of gene expression. To evaluate this approach, we developed transgenes to express highly on cells a single-chain antibody (scFv) against the hapten 4-ethoxymethylene-2-phenyl-2-oxazoline-5-one (phOx). A phOx enzyme conjugate was created by covalently attaching phOx molecules to polyethylene glycol (PEG)-modified β-glucuronidase. Cells expressing phOx scFv but not control scFv receptors were selectively killed after exposure to β-glucuronidase derivatized with phOx and PEG (phOx-βG-PEG) and a glucuronide prodrug (p-hydroxy aniline mustard β-D-glucuronide, HAMG) of p-hydroxyaniline mustard. Targeted activation of HAMG produced bystander killing of receptor-negative cells in mixed populations containing as few as 10% phOx-receptor-positive cells. Functional phOx scFv receptors were stably expressed on B16-F1 melanoma tumors in vivo. Treatment of mice bearing established phOx-receptor-positive tumors with phOx-βG-PEG and HAMG significantly (P≤.0005) suppressed tumor growth as compared with treatment with βG-PEG and HAMG or prodrug alone. phOx was unstable in the serum, suggesting alternative haptens may be more suitable for in vivo applications. Our results show that therapeutic agents can be targeted to artificial hapten receptors in vitro and in vivo. The expression of artificial receptors on target cells may allow preferential delivery of therapeutic or imaging molecules to sites of transgene expression.

頁(從 - 到)380-388
期刊Cancer Gene Therapy
出版狀態Published - 5月 2004


深入研究「Hapten-directed targeting to single-chain antibody receptors」主題。共同形成了獨特的指紋。